Tesamorelin

Tesamorelin Peptide EU

Tesamorelin is a synthetic GHRH analogue, 44 amino acids with an N-terminal trans-3-hexenoyl modification, supplied as a lyophilised powder. Free-base formula C₂₂₁H₃₆₆N₇₂O₆₇S, molar mass about 5135.9 g/mol. The approved medicine, Egrifta, has been studied for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy, with reported effects on liver fat and preservation of lean mass. Those findings concern that drug and its indication, not this vial, and they are not a dosing guide. The European application for Egrifta was withdrawn in 2012. For laboratory research only. Not for human or veterinary administration.

What Is Tesamorelin?

Tesamorelin is a synthetic peptide analogue of human growth hormone-releasing hormone, commonly abbreviated to GHRH. It contains 44 amino acids and an N-terminal trans-3-hexenoyl modification. This structural feature distinguishes the analogue from the native hormone and increases resistance to enzymatic degradation. Tesamorelin activates GHRH receptors involved in growth hormone secretion. 

For laboratory use, the material is commonly supplied as a white to off-white lyophilised powder. This presentation requires appropriate storage and preparation; it does not independently guarantee purity or stability.

The molecular formula and molecular weight above describe the free peptide. Acetate content can vary, so researchers should not assume that every supplied salt has a fixed mono-acetate composition. Check the product documentation before calculating experimental concentrations. 

What the Research Has Investigated

Research involving Tesamorelin has examined endocrine responses, including growth hormone and IGF-1 measurements. In laboratory research, relevant questions include receptor activation, downstream signalling, peptide degradation and the influence of experimental conditions.

The choice of model determines what conclusions can reasonably be drawn. A receptor-binding assay, cell-culture experiment and clinical study measure different aspects of activity. Findings from one setting should not be presented as proof of equivalent effects in another.

For research purposes, record the material’s identity, concentration, exposure time and preparation method. These details help researchers compare results with published experiments and assess whether an observed response is reproducible.

GHRH Signalling and Experimental Design

As a GHRH analogue, Tesamorelin can support investigation of pathways associated with pituitary signalling. Laboratory experiments may examine receptor responses or compare the modified peptide with a suitable reference compound.

A useful design includes appropriate controls and clearly defined endpoints. Researchers should account for receptor expression, culture conditions and the analytical method when interpreting changes in signalling.

The structural modification provides a rationale for examining peptide stability, but stability must still be assessed under the actual conditions used. Results from a formulated medicine cannot automatically establish the behaviour of an independently supplied laboratory reagent.

Distinction from Ipamorelin and CJC-1295

Tesamorelin, Ipamorelin and CJC-1295 should not be treated as interchangeable materials. Ipamorelin acts through the ghrelin receptor, whereas the other two compounds are associated with GHRH-receptor activity.

For CJC-1295, the presence or absence of an albumin-binding modification is an important identity distinction. Researchers comparing these compounds should establish the exact sequence and formulation rather than relying on abbreviated catalogue names.

A shared research topic does not mean that each peptide has the same molecular characteristics, duration of activity or preparation requirements.

Quality and Analysis

When evaluating Tesamorelin, request a batch-specific certificate of analysis supporting the stated purity. HPLC can provide information about the sample’s analytical profile, while mass spectrometry can support identity assessment.

A purity percentage alone does not establish peptide quantity, sterility or suitability for every experiment. Claims about independent testing should be supported by the relevant report.

Researchers comparing EU peptides suppliers should assess the completeness of this documentation, alongside storage guidance and transport arrangements. Confirm that a 5mg product meets the protocol’s requirements before selecting a pack size.

Storage and Preparation

Keep the lyophilised material sealed and follow the supplier’s documented storage conditions. Before opening the vial, review the preparation procedure and confirm that the proposed solvent is compatible with the assay.

Bacteriostatic water should be used only where its composition is appropriate for the experimental system. Record preparation dates, concentrations and any restrictions on storage after dissolution.

The stability of lyophilised powder does not establish a universal shelf life for prepared solutions. Laboratory procedures should address both the dried material and the conditions under which it will be tested.

Clinical Evidence and Research Material

Tesamorelin is also the active ingredient in US-approved Egrifta products for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. That approval applies to the specified medicinal products and indication; it does not confer therapeutic status on a supplier’s research material. The European marketing-authorisation application for Egrifta was withdrawn in 2012. 

Intended Use

The product described here is intended for in-vitro research use only. It must not be administered to people or animals or presented as a medicine.

Qualified researchers should follow institutional requirements for receipt, handling and disposal. Selection for laboratory research use should be based on verified identity, suitable analytical specifications and an appropriate experimental protocol.

Related Studies:

• Abdominal fat accumulation in HIV
• Fatty-liver disease in HIV
• Obesity with reduced growth-hormone secretion
• FDA-listed product information, EMA withdrawal record
• Chemical description
• Prescribing information